Latest News

MUSC Hollings researchers find that targeting an immunosuppressive protein on two fronts can reduce metastasis and restore sensitivity to immunotherapy.

An MUSC children’s cancer specialist and other experts from across state find 11% improvement in childhood cancer survival over 25-year period.

A newly approved targeted therapy for small cell lung cancer is at the forefront of a new type of drug for solid tumors.

Hollings was part of an international clinical trial that led to the FDA approval of a new drug to treat certain types of gliomas.

Two Hollings researchers are working together to develop a new way to get depression treatment to people with likely incurable cancer.

A new study aims to get a better understanding of what dual use of vapes and cigarettes looks like in real world usage.

Friends, family, colleagues and former patients gathered to honor Dr. Robert Stuart as a new outpatient bone marrow transplant clinic was named in his honor.

Facing a challenging journey with uterine cancer, Debra Morin made a list of five things to remember each day.

The Group 3 subtype of medulloblastoma has the worst prognosis of all the subtypes, but new research is pointing to a potential therapy.

Diagnosed with a rare uterine cancer at only 46, Lakisha Mack turned to faith, her family and her doctors.